Cargando…

BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis

BACKGROUND: Mutations in the gene encoding the bone morphogenetic protein receptor type II (BMPR2) are the commonest genetic cause of pulmonary arterial hypertension (PAH). However, the effect of BMPR2 mutations on clinical phenotype and outcomes remains uncertain. METHODS: We analysed individual pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Evans, Jonathan D W, Girerd, Barbara, Montani, David, Wang, Xiao-Jian, Galiè, Nazzareno, Austin, Eric D, Elliott, Greg, Asano, Koichiro, Grünig, Ekkehard, Yan, Yi, Jing, Zhi-Cheng, Manes, Alessandra, Palazzini, Massimiliano, Wheeler, Lisa A, Nakayama, Ikue, Satoh, Toru, Eichstaedt, Christina, Hinderhofer, Katrin, Wolf, Matthias, Rosenzweig, Erika B, Chung, Wendy K, Soubrier, Florent, Simonneau, Gérald, Sitbon, Olivier, Gräf, Stefan, Kaptoge, Stephen, Di Angelantonio, Emanuele, Humbert, Marc, Morrell, Nicholas W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737700/ https://www.ncbi.nlm.nih.gov/pubmed/26795434 http://dx.doi.org/10.1016/S2213-2600(15)00544-5

Ejemplares similares

Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension
por: Girerd, Barbara, et al.
Publicado: (2010)

BMPR2 Promoter Variants Effect Gene Expression in Pulmonary Arterial Hypertension Patients
por: Song, Jie, et al.
Publicado: (2020)

Mutation in BMPR2 Promoter: A ‘Second Hit’ for Manifestation of Pulmonary Arterial Hypertension?
por: Viales, Rebecca Rodríguez, et al.
Publicado: (2015)

Screening for pulmonary arterial hypertension in adults carrying a BMPR2 mutation
por: Montani, David, et al.
Publicado: (2021)

Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses
por: Galiè, Nazzareno, et al.
Publicado: (2010)

GPs Meet Rare Lung Disorders Task Force factsheet: pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers
por: Boucly, Athénaïs, et al.
Publicado: (2022)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
por: Theobald, Vivienne, et al.
Publicado: (2022)

Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH
por: Eichstaedt, Christina A., et al.
Publicado: (2023)

Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations
por: Pfarr, Nicole, et al.
Publicado: (2011)

Progress in the treatment of acute pulmonary embolism and chronic thrombo-embolic pulmonary hypertension/disease
por: Palazzini, Massimiliano, et al.
Publicado: (2023)

Identification of a New Intronic BMPR2-Mutation and Early Diagnosis of Heritable Pulmonary Arterial Hypertension in a Large Family with Mean Clinical Follow-Up of 12 Years
por: Hinderhofer, Katrin, et al.
Publicado: (2014)

EIF2AK4 mutation as “second hit” in hereditary pulmonary arterial hypertension
por: Eichstaedt, Christina A., et al.
Publicado: (2016)

A meta-analysis of randomized controlled trials in pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2009)

A Combined Targeted and Whole Exome Sequencing Approach Identified Novel Candidate Genes Involved in Heritable Pulmonary Arterial Hypertension
por: Barozzi, Chiara, et al.
Publicado: (2019)

Mutually reinforcing effects of genetic variants and interferon-β 1a therapy for pulmonary arterial hypertension development in multiple sclerosis patients
por: Lerche, Marianne, et al.
Publicado: (2019)

Pulmonary arterial hypertension
por: Montani, David, et al.
Publicado: (2013)

Right Heart Size and Right Ventricular Reserve in Pulmonary Hypertension: Impact on Management and Prognosis
por: Grünig, Ekkehard, et al.
Publicado: (2020)

New horizons in pulmonary arterial hypertension management
por: McLaughlin, Vallerie, et al.
Publicado: (2014)

A paradigm shift in pulmonary arterial hypertension management
por: Rubin, Lewis J., et al.
Publicado: (2013)

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri(®)): a prospective, 6-months, open label, observational, non-interventional study
por: Degering, Julia, et al.
Publicado: (2023)

Pulmonary Arterial Hypertension Associated with Portal Hypertension and HIV Infection: Comparative Characteristics and Prognostic Predictors
por: Dardi, Fabio, et al.
Publicado: (2023)

An overview of the 6th World Symposium on Pulmonary Hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Improving patient outcomes in pulmonary hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

A rare case of sarcoidosis-associated pulmonary hypertension in a patient exposed to silica
por: Bourlier, Delphine, et al.
Publicado: (2016)

Reply to Jha
por: Montani, David, et al.
Publicado: (2022)

Pulmonary hypertension associated with neurofibromatosis type 1
por: Jutant, Etienne-Marie, et al.
Publicado: (2018)

A pragmatic approach to risk assessment in pulmonary arterial hypertension using the 2015 European Society of Cardiology/European Respiratory Society guidelines
por: Dardi, Fabio, et al.
Publicado: (2021)

The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations
por: Dunmore, Benjamin J., et al.
Publicado: (2013)

Heritable pulmonary hypertension: from bench to bedside
por: Girerd, Barbara, et al.
Publicado: (2017)

Acute decompensated pulmonary hypertension
por: Savale, Laurent, et al.
Publicado: (2017)

The effect of exercise training and physiotherapy on left and right heart function in heart failure with preserved ejection fraction: a systematic literature review
por: Palevičiūtė, Eglė, et al.
Publicado: (2022)

Circulating MicroRNA Markers for Pulmonary Hypertension in Supervised Exercise Intervention and Nightly Oxygen Intervention
por: Grunig, Gabriele, et al.
Publicado: (2018)

Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension
por: Long, Lu, et al.
Publicado: (2015)

Pulmonary Hypertension Complicating Fibrosing Mediastinitis
por: Seferian, Andrei, et al.
Publicado: (2015)

Modification of Hemodynamic and Immune Responses to Exposure with a Weak Antigen by the Expression of a Hypomorphic BMPR2 Gene
por: Park, Sung-Hyun, et al.
Publicado: (2013)

Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension
por: Souza, Rogério, et al.
Publicado: (2022)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6rk7nrsmrjujhcguq6m3f7qrpa